Iodine 131 labelled ioglycamic acid (Biligram) for scintiscanning in hepatobiliary disorders.
Iodine-131 labelled Biligram has been evaluated as a radiopharmaceutical for dynamic scintiscanning of the liver and biliary tract. In 10 normal subjects there was good visualisation of the liver and gallbladder. In 18 patients 131I Biligram was found to be unsatifactory for differentiating parenchymal liver disease from biliary tract obstruction owing to inability to demonstrate the gallbladder when liver function was more than mildly deranged. Quantitative analyses of blood clearance and hepatic activity curves for 131I Biligram were not clinically helpful. Urinary excretion of 131I Biligram increased with the degree of hepatic dysfunction.
D001660:Biliary Tract Diseases / Q000000981:diagnostic imaging*; D003937:Diagnosis, Differential; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes / Q000378:metabolism; D007463:Iodobenzoates; D007471:Ioglycamic Acid / Q000378:metabolism; D007700:Kinetics; D008107:Liver Diseases / Q000000981:diagnostic imaging* / Q000503:physiopathology; D011877:Radionuclide Imaging
D007457:Iodine Radioisotopes; D007463:Iodobenzoates; D007471:Ioglycamic Acid